TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17719849

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised control trials (RCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethics committee approval
Number of subjects: 0
Study: 17004410

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) at 1.75 atm abs (n=57)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group receiving air at 1.3 atm abs (n=54)
Number of subjects: 111
Study: 14522286

Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Tecnis Z‐9000)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Acrylic IOL (AcrySof SA60AT)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Silicone IOL (AA4207VF)
Number of subjects: 221
Study: 10907671

Group type: COMPARATOR
Intervention: Grapefruit juice (600 ml/day) in healthy volunteers
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (600 ml/day) in patients with anxiety disorders
Number of subjects: 19
Study: 8615108

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Active physical therapy (APT)
Number of subjects: 68
Study: 1418829

Group type: EXPERIMENTAL
Intervention: Chronic magnesium administration (15.8 mmol/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6140935

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29962492

Group type: EXPERIMENTAL
Intervention: Community-wide intervention for frailty prevention
Number of subjects: 15500

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 15500
Study: 28787224

Group type: EXPERIMENTAL
Intervention: youth-physical activity toward health intervention
Number of subjects: 482
Study: 27207107

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1250 mg/m² i.v., days 1 and 8) and cisplatin (75 mg/m² i.v., day 1) plus necitumumab (800 mg i.v., days 1 and 8)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Gemcitabine (1250 mg/m² i.v., days 1 and 8) and cisplatin (75 mg/m² i.v., day 1) alone
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Gemcitabine-cisplatin plus necitumumab
Number of subjects: 982
Study: 24972789

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 100
Study: 22527887

Group type: EXPERIMENTAL
Intervention: Pasireotide 50 μg sc qd for 14 days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pasireotide 200 μg sc qd for 14 days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc qd for 14 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 20861810

Group type: EXPERIMENTAL
Intervention: Higher doses of radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More conformal radiation therapy techniques (intensity‐modulated radiation therapy, proton therapy, stereotactic body radiotherapy, brachytherapy)
Number of subjects: 0
Study: 18926160

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 746

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Continuous ECG monitoring
Number of subjects: 746
Study: 16299240

Group type: EXPERIMENTAL
Intervention: Weekly oral aminopterin, 2 mg/m2, given in two doses 12 hours apart.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Aminopterin (in vitro)
Number of subjects: 46
Study: 12623851

Group type: EXPERIMENTAL
Intervention: RIT with 100 mg alemtuzumab in vivo over 5 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Myeloablative allografts with 20 mg alemtuzumab added in vitro to the stem cells prior to return
Number of subjects: 2
Study: 10599980

Group type: EXPERIMENTAL
Intervention: Standard meal producing lower postprandial hyperglycemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standard meal producing higher postprandial hyperglycemia
Number of subjects: 10
Study: 7826271

Group type: EXPERIMENTAL
Intervention: Severe carotid artery stenosis
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Mild carotid artery stenosis
Number of subjects: 2394

Group type: COMPARATOR
Intervention: History of hypertension
Number of subjects: 2394

Group type: COMPARATOR
Intervention: History of myocardial infarction
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 2394
Study: 2201659

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine, 2 g/day for three months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7042126

Group type: EXPERIMENTAL
Intervention: 0.1% benzydamine plus tricetol as preservative
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.1% benzydamine alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31657080

Group type: EXPERIMENTAL
Intervention: Educational program and multidisciplinary care program
Number of subjects: 0
Study: 30222518

Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 300

Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 300
Study: 30584292

Group type: EXPERIMENTAL
Intervention: Slow Deep-Breathing Technique (SDBT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fast Deep-Breathing Technique (FDBT)
Number of subjects: 30
Study: 26960786

Group type: EXPERIMENTAL
Intervention: Intramuscular therapy of 1 ml Vitamin B12 (2500 mcg) weekly for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo isotonic saline 01 ml intramuscular
Number of subjects: 40
Study: 24316677

Group type: EXPERIMENTAL
Intervention: LINE1 methylation quartiles (Q2-Q4) in male smokers
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: LINE1 methylation quartiles (Q2-Q4) in male smokers (ATBC validation)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: LINE1 methylation quartiles (Q2-Q4) pooled analysis of PLCO and ATBC male smokers
Number of subjects: 580

Group type: COMPARATOR
Intervention: LINE1 methylation quartile (Q1)
Number of subjects: 580
Study: 21788032

Group type: EXPERIMENTAL
Intervention: Mitral repair in addition to coronary artery bypass grafting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 0
Study: 19854729

Group type: EXPERIMENTAL
Intervention: Higher baseline heart rate
Number of subjects: 11256

Group type: EXPERIMENTAL
Intervention: Impaired baseline creatinine clearance
Number of subjects: 11256

Group type: EXPERIMENTAL
Intervention: Prior MI
Number of subjects: 11256

Group type: EXPERIMENTAL
Intervention: Initial left ventricular ejection fraction <40%
Number of subjects: 11256

Group type: EXPERIMENTAL
Intervention: Recurrent cardiovascular events
Number of subjects: 11256

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation post-MI
Number of subjects: 11256
Study: 17963624

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 173
Study: 16239177

Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 107

Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Hormone treatment (no identified underlying aetiology)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Vigabatrin (no identified underlying aetiology)
Number of subjects: 107
Study: 12404749

Group type: EXPERIMENTAL
Intervention: Simple dietary education
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional dietary education
Number of subjects: 68
Study: 10489049

Group type: EXPERIMENTAL
Intervention: 2 x 25 mg acetylsalicylic acid (ASA)
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: 2 x 200 mg dipyridamole (DP)
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: Combination of 50 mg ASA and 400 mg DP
Number of subjects: 6602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study: 9123900

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Orimeten
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Diethyl-stilbestrol
Number of subjects: 1332
Study: 1924052

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Frusemide 40 mg once daily
Number of subjects: 12
Study: 7117676

Group type: EXPERIMENTAL
Intervention: Slow-release frusemide (twice-daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Slow-release frusemide (once-daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31731368

Group type: EXPERIMENTAL
Intervention: ETV + ADV (0.5 mg + 10 mg per day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TDF (300 mg per day)
Number of subjects: 100
Study: 28766016

Group type: EXPERIMENTAL
Intervention: TACE with miriplatin
Number of subjects: 257

Group type: COMPARATOR
Intervention: TACE with epirubicin
Number of subjects: 257
Study: 27490918

Group type: EXPERIMENTAL
Intervention: 50 mg/d soy isoflavones
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 24668328

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil arm (n = 215)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: irinotecan plus cisplatin arm (n = 216)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: S-1 arm (n = 219)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Low-risk group (0 or 1 risk factor, n = 225)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Moderate-risk group (2 or 3 risk factors, n = 368)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: High-risk group (all 4 risk factors, n = 57)
Number of subjects: 650
Study: 22813645

Group type: EXPERIMENTAL
Intervention: Immediate (early) therapy with ART initiated upon enrollment plus HIV primary care
Number of subjects: 1763

Group type: COMPARATOR
Intervention: Delayed therapy with HIV primary care but ART initiated later
Number of subjects: 1763
Study: 21140357

Group type: EXPERIMENTAL
Intervention: Leukocyte‐depleting filter
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (without leukocyte‐depleting filter)
Number of subjects: 52
Study: 17997834

Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention (FATaintPHAT)
Number of subjects: 20
Study: 15501923

Group type: EXPERIMENTAL
Intervention: Long-term head-down-tilt bed rest (HDT) for 120 days
Number of subjects: 6
Study: 11896120

Group type: EXPERIMENTAL
Intervention: CVI 5‐FU (300 mg/m² CVI for 7 days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Oral eniluracil/5‐FU (10:1 mg/m² BID for 7 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Eniluracil/5‐FU (BID for 28 days)
Number of subjects: 33
Study: 11905937

Group type: EXPERIMENTAL
Intervention: 6% CHO solution
Number of subjects: 7

Group type: COMPARATOR
Intervention: Non-caloric placebo
Number of subjects: 7
Study: 9892912

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 55

Group type: COMPARATOR
Intervention: Terbinafine
Number of subjects: 55
Study: 8116715

Group type: EXPERIMENTAL
Intervention: Korotkoff phase IV
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Korotkoff phase V
Number of subjects: 1194
Study: 3421205

Group type: EXPERIMENTAL
Intervention: Experimental diets measured by food weighing and bomb calorimetry for 56 or 42 days.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Time-series analysis of food intake during menstrual cycle phases.
Number of subjects: 23
Study: 5470432

Group type: EXPERIMENTAL
Intervention: oral oestrogen-gestogen combination
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 84147

Group type: EXPERIMENTAL
Intervention: 50 mg intravaginal prostaglandin F2 alpha (P.G.F.2 alpha) in a methyl cellulose gel
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30431499

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 64
Study: 29346385

Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Safe flooring (WASH intervention)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Latrine access (WASH intervention)
Number of subjects: 701

Group type: COMPARATOR
Intervention: WASH conditions (general)
Number of subjects: 701
Study: 28000203

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural block (TEA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Percutaneous continuous paravertebral block (PVB)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 51
Study: 25148838

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2003

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2003
Study: 22759880

Group type: EXPERIMENTAL
Intervention: Vinorelbine 60 mg/m² p.o. + Gemcitabine 1000 mg/m² i.v. on days 1 and 8 (VG)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Vinorelbine 60 mg/m² p.o. + Carboplatin AUC=5 i.v. on day 1 (VC)
Number of subjects: 444
Study: 20467309

Group type: EXPERIMENTAL
Intervention: Reflexology (4 weeks, 4 sessions, 30 minutes each, 5-9 days interval)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo (4 weeks, 4 sessions, 30 minutes each, 5-9 days interval)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 318
Study: 17878473

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational drugs or devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical pathways or protocolized-care
Number of subjects: 0
Study: 15732025

Group type: EXPERIMENTAL
Intervention: Digitalis treatment
Number of subjects: 6797

Group type: EXPERIMENTAL
Intervention: Digitalis treatment with propensity analysis
Number of subjects: 6797
Study: 12074253

Group type: EXPERIMENTAL
Intervention: Egg (640 mg additional dietary cholesterol per day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (0 mg additional dietary cholesterol per day)
Number of subjects: 51
Study: 10414766

Group type: EXPERIMENTAL
Intervention: Viscoelastic heel orthosis
Number of subjects: 22
Study: 7734355

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 125

Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 125
Study: 2183617

Group type: EXPERIMENTAL
Intervention: ampicillin 2 gm
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: cefazolin 2 gm
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: piperacillin 4 gm
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: cefotetan 1 gm
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: single-dose cephalosporin antibiotic prophylaxis
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: rupture of amniotic membranes for a half hour or more
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: internal fetal monitoring
Number of subjects: 1580
Study: 7311392

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (75 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Phenytoin (300 mg/d)
Number of subjects: 7
Study: 31194627

Group type: EXPERIMENTAL
Intervention: Video instructions (n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Handout instructions (n = 22)
Number of subjects: 45
Study: 31256122

Group type: EXPERIMENTAL
Intervention: Dementia group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dementia group (fallers)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cognitively-healthy controls
Number of subjects: 45
Study: 27593525

Group type: EXPERIMENTAL
Intervention: High glycaemic index (HGI) diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low glycaemic index (LGI) diet
Number of subjects: 8
Study: 25732936

Group type: EXPERIMENTAL
Intervention: Web-based app (eBalance)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (introductory lecture)
Number of subjects: 99
Study: 24935294

Group type: EXPERIMENTAL
Intervention: everolimus 1.5 mg (targeted C0 of 3‐8 ng/mL) plus reduced‐dose cyclosporine
Number of subjects: 11

Group type: COMPARATOR
Intervention: mycophenolate mofetil 2 g/d plus standard‐dose cyclosporine
Number of subjects: 11
Study: 22382155

Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19356621

Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A half-dose (25 microg/0.25 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A full-dose (50 microg/0.5 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control rabies vaccine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A (both doses)
Number of subjects: 60
Study: 17644511

Group type: EXPERIMENTAL
Intervention: CoQ(10) supplementation (300 mg/day for 1 month)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 16167252

Group type: EXPERIMENTAL
Intervention: Minimally invasive operation group (through spatium intermuscular of anal sphincter)
Number of subjects: 192
Study: 12358921

Group type: EXPERIMENTAL
Intervention: Cytotoxic consolidation chemotherapy following tandem transplants (TT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Dexamethasone +/‐ interferon post TT
Number of subjects: 75
Study: 10616229

Group type: EXPERIMENTAL
Intervention: Melatonin administration
Number of subjects: 0
Study: 7772356

Group type: EXPERIMENTAL
Intervention: Droperidol 300 mcg/kg orally
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Droperidol 300 mcg/kg and Metoclopramide 0.15 mg/kg orally
Number of subjects: 154

Group type: COMPARATOR
Intervention: Metoclopramide 0.15 mg/kg orally
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 2079382

Group type: EXPERIMENTAL
Intervention: Troxerutine, single oral dose
Number of subjects: 0
Study: 656731

Group type: EXPERIMENTAL
Intervention: Rewarding conditions ('good' and 'buzzer' for sociability; 'good' for impulsivity)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Punishing conditions ('electric shock')
Number of subjects: 120
Study: 29512784

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen gel and oral aspirin combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transdermal estrogen only therapy
Number of subjects: 0
Study: 27189087

Group type: EXPERIMENTAL
Intervention: Tian Jiu therapy (TJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 0
Study: 24973289

Group type: EXPERIMENTAL
Intervention: Oximeter masking algorithm
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Higher target group (92%)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Lower target group (88%)
Number of subjects: 1075
Study: 22570264

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 19770778

Group type: EXPERIMENTAL
Intervention: Electronic compliance monitoring with a reminder and monitoring device
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Electronic compliance monitoring with a reminder and monitoring device after crossover
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard therapy after crossover
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Electronic monitoring data on compliance (study group 1)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard therapy (study group 2)
Number of subjects: 398
Study: 17570265

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sedentary control group for 8 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 19
Study: 16275007

Group type: COMPARATOR
Intervention: Conventional valves
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Silzone group
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Valve suture technique without pledgets
Number of subjects: 807

Group type: COMPARATOR
Intervention: Valve suture technique with pledgets
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Suture technique without pledgets
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Silzone cuff
Number of subjects: 807
Study: 11856388

Group type: EXPERIMENTAL
Intervention: Endosseous implant systems (IMZ, Brånemark, Transmandibular)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Endosseous implant systems (IMZ, Brånemark)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Transmandibular Implant system
Number of subjects: 235
Study: 10452767

Group type: EXPERIMENTAL
Intervention: cetirizine 0.25 mg/kg twice daily
Number of subjects: 817

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 817
Study: 8529776

Group type: EXPERIMENTAL
Intervention: Loperamide oxide (2 mg initially, then 1 mg after each unformed stool, mean daily dose 2.7 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2129489

Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil b.d. (part 1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (part 1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil b.d. (part 2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 70 micrograms enprostil b.d. (part 2)
Number of subjects: 17
Study: 382433

Group type: EXPERIMENTAL
Intervention: Heparin 5,000 IU subcutaneously twice daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study: 31604623

Group type: EXPERIMENTAL
Intervention: 3-way stopcock (TWS) connectors
Number of subjects: 180

Group type: COMPARATOR
Intervention: Needleless connectors (NC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Other types of connectors or catheters
Number of subjects: 180